Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

Alcon Research138 enrolled

Overview

The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

138

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

Travoprost ophthalmic solution, 0.0008%DRUG

Travoprost ophthalmic solution, 0.001%DRUG

Travoprost ophthalmic solution, 0.0012%DRUG

TRAVATAN

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 years of age or older, either sex or race with open-angle glaucoma or confirmed ocular hypertension * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Age related * Other protocol-defined exclusion criteria may apply

Locations (1)

Contact Alcon Call Center at 1-888-451-3937

Fort Worth, Texas, United States

Outcomes

Primary Outcomes

Mean Intraocular Pressure

Time frame: Up to 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.